Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is an open label study to determine the safety and preliminary evidence of a therapeutic
effect of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent
radiation and temozolomide.